Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Vestibular schwannomas are primarily benign (WHO grade I) tumors originating from the Schwann cells of the vestibular nerve and are among the most common tumors of the skull base. Common treatment options are surgical tumor resection or targeted radiation therapy. The special challenge of surgical treatment is the functional preservation of the cranial nerves, especially the cochlear and facial nerves. Perioperative ischemia of the cochlea and cochlear nerve is postulated as the underlying mechanism of postoperative hearing loss. Ischemic preconditioning is a non-invasive procedure that triggers the release of vasoactive cytokines and mediators by repeated short-term induction of limb ischemia. Improved perfusion of critically perfused end organs as well as a reduction of cerebral infarct volumes has already been shown in other pathologies. In the planned study, possible neuroprotective effects of remote ischemic preconditioning on postoperative hearing as well as facial nerve function in patients with vestibular schwannomas will be examined.
Purpose: Does remote ischemic preconditioning improve hearing and/or facial nerve palsy after resection of vestibular schwannomas?
Study Design: Prospective, randomized, double-blind, single-center.
Case number: The study should include 120 patients (60 treatment arm, 60 control arm). Case number calculation (mean effect sizes, chi-square test, alpha error = 0.05, beta error = 20%) results in a necessary total patient number of 100 with 50 patients per group. Including the expected dropout rate (approx. 20%), the required total number of study participants is set at 120 patients. With approximately 55 patients/year in whom anatomic preservation of the cochlear nerve is possible intraoperatively, the total study duration is estimated to be approximately 2-2.5 years.
Study procedure: Day 1
Day 2
Randomization
At skin incision RIC procedure or sham control.
Performance of tumor resection under electrophysiological monitoring.
blood sample (Hg, WBC, platelet count, creatinine, sodium, potassium, CRP, PCT, IL-6, INR, Quick, aPTT, d-dimer)
Day 3
Before discharge
Outpatient follow-up after 3 months
Objective:
Primary outcome: patients undergoing RIC will show better hearing 3 months postoperatively than the sham control group.
Secondary outcome hypothesis: patients undergoing RIC will show better postoperative facial nerve function than the sham control group before discharge and 3 months postoperatively.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RIC | Experimental | On the right upper extremity a blood pressure cuff is inflated to 200mmHg for 4x5min at the beginning of the surgery |
|
| Control | Sham Comparator | On the right upper extremity a blood pressure cuff is inflated to 0mmHg for 4x5min at the beginning of the surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Remote ischemic preconditioning | Procedure | A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started |
| Measure | Description | Time Frame |
|---|---|---|
| postoperative hearing | hearing on pure tone audiometry according to AAO-HNS/Gardner-Robertson | 3 months (± 6 weeks) after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| postoperative facial nerve function | facial nerve function according to House and Brackmann | up to 8 days after surgery |
| postoperative facial nerve function | facial nerve function according to House and Brackmann |
| Measure | Description | Time Frame |
|---|---|---|
| postoperative hearing | hearing on pure tone audiometry according to AAO-HNS/Gardner-Robertson | up to 8 days after surgery |
| laboratory findings | White blood count |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Helene V Hurth, MD | Contact | +49 7071 29 80325 | helene.hurth@med.uni-tuebingen.de | |
| Constantin Roder, Prof., MD | Contact | constantin.roder@med.uni-tuebingen.de |
| Name | Affiliation | Role |
|---|---|---|
| Contantin Roder, Prof., MD | Department of Neurosurgery Tuebingen | Principal Investigator |
| Helene V Hurth, MD | Department of Neurosurgery Tuebingen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Tuebingen | Tübingen | 72076 | Germany |
IPD may be shared on request after completion of the study and as soon as data will be published.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009464 | Neuroma, Acoustic |
| ID | Term |
|---|---|
| D009442 | Neurilemmoma |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
Not provided
Not provided
group 1: intervention, remote ischemic preconditioning for 4x5 minutes at the beginning of the surgery group 2: sham-control (4x5 min without compression of the extremity)
Not provided
Not provided
only the study nurse who performs the intervention is aware of the study arm
| Sham-control | Procedure | A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started |
|
| 3 months (± 6 weeks) after surgery |
| within 4 hours after surgery |
| laboratory findings | C-reactive protein | within 4 hours after surgery |
| laboratory findings | Procalcitonin | within 4 hours after surgery |
| laboratory findings | Interleukin 6 | within 4 hours after surgery |
| laboratory findings | D-Dimer | within 4 hours after surgery |
| laboratory findings | platelet count | within 4 hours after surgery |
| laboratory findings | International normalized ratio (INR) | within 4 hours after surgery |
| laboratory findings | activated partial thromboplastin time (aPTT) | within 4 hours after surgery |
| laboratory findings | White blood count | postoperatively, 1 day after surgery |
| laboratory findings | C-reactive protein | postoperatively, 1 day after surgery |
| laboratory findings | Procalcitonin | postoperatively, 1 day after surgery |
| laboratory findings | Interleukin 6 | postoperatively, 1 day after surgery |
| laboratory findings | D-Dimer | postoperatively, 1 day after surgery |
| laboratory findings | platelet count | postoperatively, 1 day after surgery |
| laboratory findings | International normalized ratio (INR) | postoperatively, 1 day after surgery |
| laboratory findings | activated partial thromboplastin time (aPTT) | postoperatively, 1 day after surgery |
| postoperative AEP | Auditory evoked potentials after surgery | up to 8 days after surgery |
| postoperative vertigo | Vertigo according to dizziness handicap inventory (=DHI, score 0-100, higher scores are associated with a higher burden of dizziness) | up to 8 days after surgery |
| postoperative vertigo | Vertigo according to dizziness handicap inventory (=DHI, score 0-100, higher scores are associated with a higher burden of dizziness) | 3 months (± 6 weeks) after surgery |
| extent of schwannoma resection | extent of schwannoma resection on the postoperative MRI | 3 months (± 6 weeks) after surgery |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009463 | Neuroma |
| D018317 | Nerve Sheath Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D003390 | Cranial Nerve Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D010524 | Peripheral Nervous System Neoplasms |
| D000160 | Vestibulocochlear Nerve Diseases |
| D012181 | Retrocochlear Diseases |
| D004427 | Ear Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D010039 | Otorhinolaryngologic Neoplasms |
| D003389 | Cranial Nerve Diseases |
| D009422 | Nervous System Diseases |